Department of Haematology, Christian Medical College, Vellore, India.
Acta Haematol. 2012;127(3):135-42. doi: 10.1159/000334716. Epub 2012 Jan 12.
Achieving a major molecular response (MMR) is an important predictor of progression-free survival in chronic myeloid leukemia patients treated with imatinib. This requires accurate measurement of BCR-ABL1 transcripts normalized to a control gene, as well as defining a level (BCR-ABL1/control gene ratio) that will correlate with sustained clinical response. To make these measurements comparable between laboratories, an international scale (IS) is necessary. A BCR-ABL1/control gene ratio of 0.10% represents MMR in the IS. In collaboration with an international reference laboratory in Adelaide, S.A., Australia, we have established and validated a lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS. In this report, we explain the process and steps involved in obtaining a valid lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS.
在接受伊马替尼治疗的慢性髓性白血病患者中，达到主要分子反应 (MMR) 是无进展生存期的重要预测指标。这需要准确测量 BCR-ABL1 转录本相对于对照基因的归一化值，以及确定与持续临床反应相关的水平（BCR-ABL1/对照基因比值）。为了使这些测量值在实验室之间具有可比性，需要使用国际标准 (IS)。BCR-ABL1/对照基因比值为 0.10% 表示在 IS 中达到 MMR。我们与澳大利亚阿德莱德的一个国际参考实验室合作，已经建立并验证了用于在 IS 中表达 BCR-ABL1 转录本水平的实验室特定转换因子。在本报告中，我们解释了获得用于在 IS 中表达 BCR-ABL1 转录本水平的有效实验室特定转换因子的过程和步骤。
